Lupin Q4 Review - Seasonality Led De-Growth In U.S., Muted Domestic Performance Due To Covid-19: KRChoksey
Duloxetine delayed-release capsules sit inside a bottle beside other empty bottles inside the packaging unit at the Lupin Ltd. (Photographer: Dhiraj Singh/Bloomberg)  

Lupin Q4 Review - Seasonality Led De-Growth In U.S., Muted Domestic Performance Due To Covid-19: KRChoksey

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

KRChoksey Research Report

Lupin Ltd. reported a marginal decline in revenue at 1.6% YoY (down 5.8% QoQ) to Rs 37,831 million in Q4 FY21 due to 5.3% YoY (up 3.7% QoQ) decline in the North America revenue to Rs 14,952 million.

The QoQ decline in total revenue, however, can be attributed to a 5.9% QoQ decline in India revenue to Rs 12,866 million.

Ebitda margin expanded by 504 basis points YoY to 18.7% in Q4 FY21 (from 13.7% in Q4 FY20) due to improved gross margins YoY.

However, Ebitda margin contracted by 68 bps QoQ, due to lower gross margins, partially offset by, stable other expenses QoQ.

Click on the attachment to read the full report:

KRChoksey Lupin Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.